Fever with chemotherapy induced neutropenia;Fieber bei chemotherapie-assoziierter Neutropenie

Therapeutische Umschau

Volumn 71, Issue 1, 2014, Pages 17-22

  Conen, Katrin ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; CEPHALOSPORIN; QUINOLONE;

CANCER PATIENT; CHEMOTHERAPY; DRUG DOSE REGIMEN; FEBRILE NEUTROPENIA; HOSPITAL ADMISSION; HOSPITAL INFECTION; HOSPITALIZATION COST; MOUTH TEMPERATURE; NEUTROPHIL COUNT; PSEUDOMONAS INFECTION; REVIEW; RISK ASSESSMENT;

ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS; CRITICAL CARE; FEVER; HUMANS; NEOPLASMS; NEUTROPENIA;

EID: 84891853762     PISSN: 00405930     EISSN: None     Source Type: Journal    
DOI: 10.1024/0040-5930/a000477     Document Type: Review

References (25)

1. Freifeld AG et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis, 2011; 52: e56-93.
2. de Naurois J et al. Management of Practice Guidelines. Ann Oncol, 2010; 21 (Suppl 5): v252-6.
3. Menichetti F. Infectious complications in neutropenic cancer patients. Intern Emerg Med, 2010; 5 (Suppl 1): S21-5.
4. Innes H et al. Management of febrile neutropenia in solid tumours and lymphomas using the Multinational Association for Supportive Care in Cancer (MASCC) risk index: feasibility and safety in routine clinical practice. Support Care Cancer, 2008; 16: 485-91.
5. Feld R. Bloodstream infections in cancer patients with febrile neutropenia. Int J Antimicrob Agents, 2008; 32 (Suppl 1): S30-3.
6. Skovbjerg S et al. Optimization of the detection of microbes in blood from immunocompromised patients with haematological malignancies. Clin Microbiol Infect, 2009; 15: 680-3.
7. Aapro MS et al. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer, 2006; 42: 2433-53.
8. Vera-Llonch M et al. Healthcare costs in patients with metastatic lung cancer receiving chemotherapy. BMC Health Serv Res, 2011; 11: 305.
9. Bucaneve G et al. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med, 2005; 353: 977-87.
10. Vidal L et al. Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients. Cochrane Database Syst Rev, 2004: CD003992.
11. Vidal L et al. Quantitative age-related changes in dorsal lateral geniculate nucleus relay neurons of the rat. Neurosci Res, 2004; 48: 387-96.
12. Kamana M et al. Bacterial infections in low-risk, febrile neutropenic patients. Cancer, 2005; 104: 422-6.
13. Elting LS et al. Outcomes and cost of outpatient or inpatient management of 712 patients with febrile neutropenia. J Clin Oncol, 2008; 26: 606-11.
14. Furno P, Bucaneve G and Del Favero A. Monotherapy or aminoglycosidecontaining combinations for empirical antibiotic treatment of febrile neutropenic patients: a meta-analysis. Lancet Infect Dis, 2002; 2: 231-42.
15. Kibbler CC and Prentice HG. Pathogen "shift" in febrile neutropenia. Curr Opin Infect Dis, 1999; 12: 351-4.
16. Wolf HH et al. Central venous catheter-related infections in hematology and oncology: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol, 2008; 87: 863-76.
17. Raad I et al. Management of the catheter in documented catheter-related coagulase-negative staphylococcal bacteremia: remove or retain? Clin Infect Dis, 2009; 49: 1187-94.
18. Jordan K et al. Venous access ports: frequency and management of complications in oncology patients. Onkologie, 2008; 31: 404-10.
19. Kovacs JA and Masur H. Evolving health effects of Pneumocystis: one hundred years of progress in diagnosis and treatment. JAMA, 2009; 301: 2578-85.
20. Ziglam HM et al. Knowledge about sepsis among training-grade doctors. J Antimicrob Chemother, 2006; 57: 963-5.
21. Herbrecht R et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med, 2002; 347: 408-15.
22. Cornely OA et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis, 2007; 44: 1289-97.
23. Freifeld A et al. A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. N Engl J Med, 1999; 341: 305-11.
24. Dockrell DH. Salvage therapy for invasive aspergillosis. J Antimicrob Chemother, 2008; 61 (Suppl 1): i41-4.
25. Torres-Madriz G and Boucher HW. Immunocompromised hosts: perspectives in the treatment and prophylaxis of cytomegalovirus disease in solid-organ transplant recipients. Clin Infect Dis, 2008; 47: 702-11.